Most Read

Upadacitinib (RINVOQ, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) is intended for those patients who have not shown adequate response, lost response or were intolerant to

Earlier, TMB-001 received orphan drug designation from the EC to treat autosomal recessive congenital ichthyosis (ARCI). Timber Pharmaceuticals chairman and CEO John Koconis said: “We are pleased to

Xspray Pharma will maintain financial and strategic control and grant exclusive commercialisation access to Eversana for supporting its Dasynoc launch. Dasynoc, pending approval from the Food and Drug

SAGE-718 is a first-in-class NMDA receptor positive allosteric modulator (PAM) as well as lead neuropsychiatric drug candidate. It is in development as a potential oral therapy for cognitive

Said to be the company’s first combination vaccine candidate, IVX-A12 targets RSV as well as hMPV, which are two of the top five causes of pneumonia in adult

The regulatory agency has ascertained that the application is sufficiently finished to allow a substantive review. Valneva, a specialty vaccine company, stated that the review is classified as

The once-daily oral medication FILSPARI has been designed to target two critical pathways selectively in the disease progression of IgAN (endothelin-1 and angiotensin II). It is said to

In September last year, Stimufend received approval from the US Food and Drug Administration (FDA) to be used in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs that

Under the terms of the agreement, Coya obtained the rights for the development and commercialisation of its product COYA 301 as a single agent to treat several autoimmune